Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:DRTX
CUSIP26658A10
WebN/A
Phone+1-312-2197000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
Durata Therapeutics (NASDAQ:DRTX) Frequently Asked Questions
What is Durata Therapeutics' stock symbol?
Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."
Has Durata Therapeutics been receiving favorable news coverage?
Media headlines about DRTX stock have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Durata Therapeutics earned a coverage optimism score of 0.14 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 48.42 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Durata Therapeutics.
How do I buy shares of Durata Therapeutics?
Shares of DRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Durata Therapeutics?
Durata Therapeutics' mailing address is 200 S Wacker Dr Ste 2550, CHICAGO, IL 60606-5811, United States. The biotechnology company can be reached via phone at +1-312-2197000.
MarketBeat Community Rating for Durata Therapeutics (NASDAQ DRTX)
MarketBeat's community ratings are surveys of what our community members think about Durata Therapeutics and other stocks. Vote "Outperform" if you believe DRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
